CN114686444A

CN114686444A - Hybridoma cell, anti-thrombomodulin monoclonal antibody, and preparation method and application thereof

Info

Publication number: CN114686444A
Application number: CN202011638722.1A
Authority: CN
Inventors: 吴培钿; 卓业斌; 谭仙桂; 陈渤; 吕锦华
Original assignee: Guangzhou Wondfo Biotech Co Ltd
Current assignee: Guangzhou Wondfo Biotech Co Ltd
Priority date: 2020-12-31
Filing date: 2020-12-31
Publication date: 2022-07-01

Abstract

The invention relates to a hybridoma cell, an anti-thrombomodulin monoclonal antibody, a preparation method and an application thereof. The anti-TM monoclonal antibody TM2 produced by the hybridoma cell is applied to the in vitro detection of TM protein, such as the preparation of a chemiluminescence detection kit and the like, can accurately quantify the concentration of TM protein in a blood sample, and has great economic and social benefits.

Description

Hybridoma cell, anti-thrombomodulin monoclonal antibody, and preparation method and application thereof

Technical Field

The invention relates to the technical field of cells, in particular to a hybridoma cell, an anti-thrombomodulin monoclonal antibody, and preparation methods and applications thereof.

Background

Thrombomodulin (TM) is a single-chain transmembrane glycoprotein with a relative molecular mass of 75kDa and a relative molecular mass of 105kDa after degradation of disulfide bonds. The gene is located in the 20 th pair of autosomes, contains 18 exons and no introns, has the length of 3.7kb, can transcribe the base 1725bp, and the expression product consists of 575 amino acids. Wherein the serine, threonine domain or O is enriched₂The binding sugar chain region is an attachment site of a heparin-like polysaccharide structure on a TM molecule, has close relation with the thrombin inhibition activity of the TM, and is possibly a second binding site of thrombin on the TM molecule. The 23 amino acid transmembrane domain consists mainly of hydrophobic amino acids, and has no other homologous sequences of known receptor proteins, while the C-terminal cytoplasmic domain is involved in degradation and endocytosis of the TM. TM was originally found in vascular endothelial cells. Immunohistochemical staining demonstrated that greater than about 99% of vascular endothelial cells express TM, with (0.3-1.0) x 10 per endothelial cell⁵A TM molecule. Recent studies have found that TM is also present in placental trophoblast cells, platelets, megakaryocytes, monocytes, neutrophils, synovial cells, keratinocytes, meningeal cells, smooth muscle cells, tumor cells.

The expression of TM is regulated by a series of mechanisms, TM is only present in a portion of the cells in vivo, and this tissue-specific expression may be controlled by promoters unique to TM genes, with alterations in transcription rate and translation also affecting quantitative expression. Cal found that cellular TM antigen and TM mRNA levels after Vascular Endothelial Growth Factor (VEGF) treatment were increased by approximately 2.5-fold and PC activation efficiency was increased by 50-80%. Meanwhile, VEGF can block the inhibition of IL21 on the expression of TM antigen and mRNA, and resist the down-regulation effect of TGF2 beta and lipopolysaccharide on the expression of TM. 1,25 dihydroxy vitamin D3 and its derivatives can also inhibit monocyte TF expression and up-regulate TM expression. TM exists in two forms, namely, the immobilized form (membrane form) and the solubilized form (blood form). The former is present on the cell surface and the latter is free in plasma and urine. The relative molecular mass of TM in plasma and urine is different in magnitude. TM is a recently discovered transmembrane glycoprotein present on the surface of vascular endothelial cells, and plays an important role in the body's anticoagulant mechanism. As a member of cell adhesion molecules, TM is also involved in regulating the development, progression and metastasis of tumor cells. Therefore, TM has been regarded as a marker of endothelial cell injury in medicine, is used for diagnosis and identification of clinical diseases, and has important index significance for diagnosis of diseases and measurement of treatment conditions.

Disclosure of Invention

Accordingly, there is a need for a hybridoma cell that secretes an anti-thrombomodulin monoclonal antibody having high epitope selectivity and high holoprotein affinity.

The invention provides a hybridoma cell capable of secreting an anti-thrombomodulin monoclonal antibody, which has the preservation number of CCTCC NO: C202064.

the invention also provides an anti-thrombomodulin monoclonal antibody secreted by the hybridoma cell, and the anti-thrombomodulin monoclonal antibody is marked as TM 2.

The invention also provides a preparation method of the anti-thrombomodulin monoclonal antibody, which comprises the following steps: injecting the hybridoma cells into the abdominal cavity of a mouse, collecting ascites, separating and purifying to obtain the anti-thrombomodulin monoclonal antibody.

In one embodiment, the intraperitoneal injection is performed by injecting 4X 10 per mouse⁵～6×10⁵And (c) the hybridoma cells.

The invention also provides application of the hybridoma cell or the anti-thrombomodulin monoclonal antibody in preparation of a product for detecting thrombomodulin.

The invention also provides a thrombomodulin detection kit, which comprises the anti-thrombomodulin monoclonal antibody.

In one embodiment, the thrombomodulin detection kit further comprises magnetic particles and alkaline phosphatase.

In one embodiment, the thrombomodulin detection kit further comprises Tween and phosphate buffer.

The invention also provides a preparation method of the hybridoma cell, which comprises the following steps:

a mouse is immunized for the first time by taking thrombomodulin as an immunogen, wherein the amino acid sequence of the thrombomodulin is shown as SEQ ID NO: 1 is shown in the specification;

and carrying out at least two times of boosting immunization and one time of impact immunization on the mice immunized for the first time by taking the thrombomodulin core fragment as an immunogen, wherein the amino acid sequence of the thrombomodulin core fragment is shown as SEQ ID NO: 3 is shown in the specification;

and (3) taking spleen cells of the mouse immunized by the impact, fusing the spleen cells with myeloma cells, and screening to obtain hybridoma cells stably secreting the anti-thrombomodulin monoclonal antibody TM 2.

It has been found that TM exists mostly in free form in human plasma, a small fraction of which binds thrombin and has different molecular weight fragments, and therefore monoclonal antibodies with good epitope selectivity and high holoprotein affinity need to be screened if they are to be quantified immunologically accurately. However, the general TM monoclonal antibody has poor epitope selectivity and low affinity, cannot accurately recognize thrombomodulin present in different forms in a sample, and is not highly accurate in quantification. The invention provides a hybridoma cell obtained by screening, and a monoclonal antibody secreted by the hybridoma cell has good surface selectivity and high holoprotein affinity. The anti-TM monoclonal antibody TM2 produced by the hybridoma cell is applied to the in vitro detection of TM protein, such as the preparation of a chemiluminescence detection kit and the like, can accurately quantify the concentration of TM protein in a blood sample, and has great economic and social benefits.

Drawings

FIG. 1 is a graph showing the result of measuring the tail blood titer of an immunized mouse in the examples;

FIG. 2 is a graph showing the results of titer determination of TM1 and TM2 antibodies in examples;

FIG. 3 is a graph showing the results of sensitivity measurement of the antibodies TM1, TM2 and TM3 in examples;

FIG. 4 is a standard curve of thrombomodulin in examples;

FIG. 5 is a graph showing the correlation between the test agent and 100 clinical samples of the chemiluminescent reagent of Sysmex in the examples.

Detailed Description

In order that the invention may be more fully understood, a more particular description of the invention will now be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

The hybridoma capable of secreting the anti-thrombomodulin monoclonal antibody according to an embodiment of the present invention is preserved in the China Center for Type Culture Collection (CCTCC) at 5, month and 18 days of 2020, with a preservation number of CCTCC NO: c202063, address China, Wuhan university. The hybridoma cell can secrete an anti-thrombomodulin monoclonal antibody, which is marked as TM1, TM1 can be used as a detection antibody of thrombomodulin, and the hybridoma cell can be applied to the preparation field of products such as detection kits or detection equipment of the thrombomodulin.

Anti-thrombomodulin-one-gram according to one embodiment of the present inventionThe preparation method of the cloned antibody TM1 comprises the following steps: injecting the hybridoma cells into the abdominal cavity of a mouse, collecting ascites, separating and purifying to obtain the anti-thrombomodulin monoclonal antibody TM 1. Preferably, when intraperitoneal injection is carried out, 4X 10 is injected into each mouse⁵～6×10⁵And (3) hybridoma cells.

The thrombomodulin detection kit of an embodiment of the present invention includes the above-described anti-thrombomodulin monoclonal antibody TM 1.

In a specific example, the thrombomodulin detection kit further comprises a nucleic acid sequence with a collection number of CCTCC NO: the monoclonal antibody TM2 secreted by the hybridoma cell of C202064.

In one particular example, the thrombomodulin detection kit further comprises magnetic particles and alkaline phosphatase. Specifically, the thrombomodulin detection kit comprises a first detection solution and a second detection solution, wherein the first detection solution contains an anti-thrombomodulin monoclonal antibody TM1 coated by magnetic particles, and the second detection solution contains an anti-thrombomodulin monoclonal antibody TM2 marked by alkaline phosphatase. It is understood that the substance for coating the antibody is not limited to the magnetic particles, and the substance for labeling the antibody is not limited to alkaline phosphatase, and other commonly used coatings and labels may be used. During detection, the first detection solution and the second detection solution are added into a sample to be detected, the anti-thrombomodulin monoclonal antibodies TM1 and TM2 are respectively directed at different thrombomodulin epitopes, thrombomodulin in the sample to be detected can be sandwiched between the antibodies TM1 and TM2, the content of the thrombomodulin in the sample to be detected can be determined according to a luminous signal of alkaline phosphatase, and the reduction of detection accuracy caused by shielding of part of the epitopes on the thrombomodulin can be avoided.

In one specific example, the first detection solution is prepared by the following method: the magnetic particles, the anti-thrombomodulin monoclonal antibody TM1 and the binding buffer were mixed and cultured overnight with shaking. And removing the supernatant after incubation, blocking the residual binding sites on the magnetic particles by Bovine Serum Albumin (BSA), washing, and dispersing in a detection buffer.

In one specific example, the second detection solution is prepared by the following method: alkaline phosphatase, anti-thrombomodulin monoclonal antibody TM2 and water were mixed, added with a phosphate buffer solution containing glutaraldehyde, and incubated in the dark with gentle shaking. Then add monoethanolamine solution and shake incubation, then dialyze overnight at low temperature against phosphate buffer, mix with equal volume of glycerol and 1% BSA.

The method for preparing the hybridoma according to an embodiment of the present invention includes the following steps S1 to S3:

s1, taking the mouse to immunize for the first time by taking thrombomodulin as immunogen, wherein the amino acid sequence of the thrombomodulin is shown as SEQ ID NO: 1 is shown.

S2, carrying out at least two times of boosting immunity and one time of impact immunity on the mice immunized for the first time by taking the N-terminal fragment of the thrombomodulin as an immunogen, wherein the amino acid sequence of the N-terminal fragment of the thrombomodulin is shown as SEQ ID NO: 2, respectively.

S3, spleen cells of the mouse after the impact immunization are taken to be fused with myeloma cells, and hybridoma cells which stably secrete the anti-thrombomodulin monoclonal antibody TM1 are obtained by screening.

In one embodiment, thrombomodulin, the N-terminal fragment of thrombomodulin and the core fragment of thrombomodulin are obtained by the steps of gene cloning, plasmid construction, transfection, host expression, isolation and purification.

In one particular example, the way spleen cells are fused with myeloma cells is by electrofusion.

The hybridoma capable of secreting the anti-thrombomodulin monoclonal antibody according to another embodiment of the present invention is preserved in China Center for Type Culture Collection (CCTCC) at 5, month and 18 days of 2020, with a preservation number of CCTCC NO: c202064, address China, Wuhan university. The hybridoma cell can secrete an anti-thrombomodulin monoclonal antibody, which is marked as TM2, TM2 can be used as a detection antibody of thrombomodulin, and the hybridoma cell can be applied to the preparation field of products such as detection kits or detection equipment of the thrombomodulin.

The preparation method of the anti-thrombomodulin monoclonal antibody TM2 in one embodiment of the invention comprises the following steps: to the direction ofInjecting the hybridoma cells into the abdominal cavity of a mouse, collecting ascites, separating and purifying to obtain the anti-thrombomodulin monoclonal antibody TM 2. Preferably, when intraperitoneal injection is carried out, 4X 10 is injected into each mouse⁵～6×10⁵And (3) hybridoma cells.

The thrombomodulin detection kit of an embodiment of the present invention comprises the above-mentioned anti-thrombomodulin monoclonal antibody TM 2. In one particular example, the thrombomodulin detection kit further comprises magnetic particles and alkaline phosphatase.

S2, performing at least two times of boosting immunity and one time of impact immunity on the mice immunized for the first time by taking the thrombomodulin core segment as an immunogen, wherein the amino acid sequence of the thrombomodulin core segment is shown as SEQ ID NO: 3, respectively.

S3, taking spleen cells of the mouse after the shock immunization, fusing the spleen cells with myeloma cells, and screening to obtain hybridoma cells which stably secrete the anti-thrombomodulin monoclonal antibody TM 2.

It has been found that TM exists mostly in free form in human plasma, a small fraction of which binds thrombin and has different molecular weight fragments, and therefore monoclonal antibodies with good epitope selectivity and high holoprotein affinity need to be screened if they are to be quantified immunologically accurately. However, the general TM monoclonal antibody has poor epitope selectivity and low affinity, and cannot accurately recognize thrombomodulin present in different forms in a sample, and the quantitative accuracy is not high. The invention provides two hybridoma cells obtained by screening, and the monoclonal antibody secreted by the hybridoma cells has good surface selectivity and high holoprotein affinity. The anti-TM monoclonal antibodies TM1 and TM2 produced by the hybridoma cells are applied to the in vitro detection of TM protein, such as the preparation of a chemiluminescence detection kit and the like, so that the concentration of the TM protein in a blood sample can be accurately quantified, and the method has great economic and social benefits.

The following are specific examples.

1 preparation of anti-thrombomodulin monoclonal antibody

1.1 antigen preparation

1.1.1 cloning of the Gene of interest

Genomic DNA is extracted from human whole blood and used as a template, and corresponding primers of a TM complete sequence, a TM-N terminal region and a core region (EGF 1-6) are respectively used for cloning a target gene. After sequencing was correct, it was ligated into pET28a (+) and transfected into HD5 α for expression testing. After confirming the expression, BL21 was used as a host to express a large amount of the target protein, and Ni-NTA affinity chromatography was performed to purify the target protein to obtain a high-purity protein. The proteins are respectively named as TM-Total, TM-NT and TM-EGF, and the amino acid sequences are respectively shown as SEQ ID NO: 1 to SEQ ID NO: 3, storing at-80 ℃ for later use.

1.2 animal immunization methods and procedures

6 female BALB/c mice of 5-6 weeks are selected, after primary immunization is finished by using TM-Total, the female BALB/c mice are divided into two groups, 3 mice in each group are respectively subjected to three times of boosting immunization by using TM-NT and TM-EGF, and on the seventh day after the three times of immunization, tail blood is taken for serum titer detection, and the result is shown in figure 1. The mice with the highest titer were selected for ballistic fusion, and the immunization procedure is shown in table 1.

TABLE 1 summary of protein immunization information

1.3 fusion of splenocytes with myeloma cells

One week before fusion, frozen myeloma cells (SP2/0) are recovered by a conventional cell recovery method, and then SP2/0 cells in a good state are selected and liquid is changed the day before fusion. Spleen cells of mice with the immune titer meeting the requirement are taken and placed on a sterile screen. The spleen was ground with a syringe core, and 1640 incomplete medium was added dropwise while grinding, and ground until only white visceral membranes remained. Spleen cells were collected into a 50mL centrifuge tube, centrifuged at 1200rpm for 5min, the supernatant was discarded, collected and resuspended. SP2/0 was resuspended in 10mL of incomplete medium after centrifugation with spleen cells, and counted by dilution. The optimum ratio is 1:1 to 1: and 4, mixing the two cells according to the proportion. Centrifuge at 1200rpm for 5min and discard the supernatant. Resuspending and mixing the mixture by ECF Buffer, then centrifuging the mixture at low speed of 1200r/min for 5min, and removing supernatant. The ECF Buffer wash was repeated. Finally, it was resuspended in 6.4mL of ECF Buffer for use. And (3) switching on a power supply of the electric fusion instrument, pressing an omega key, and measuring the resistance, wherein the resistance value is more than 2K omega. 6.4ml of the cell mixture resuspended in ECF Buffer was added. Note that the dropping should be slow so as not to generate bubbles to affect the resistance. Pressing the "omega" key confirms that the resistance value is between 0.8K omega and 2K omega. Pressing the Start key after no error, and waiting for the completion of the electrofusion prompt. After the electric shock is finished, the cell mixed solution is transferred into 12.8mL of repairing solution to repair and destroy cell membranes. Standing at 37 deg.C (incubator) for 10 min. Note that the tip should be extended below the liquid surface during transfer, then gently removed, centrifuged at 800rpm for 5min, and the supernatant discarded. The cells were resuspended in complete medium (containing 20% fetal bovine serum, 1% HAT and appropriate proportions of feeder cells), transferred to 96-well plates, and cultured in a 37 ℃ cell incubator.

1.4 Indirect ELISA detection

The immune antigen of the immunized mouse is diluted by the coating solution, a 96-well enzyme label plate is added, 100 mu L of the antigen is added into each well, the antigen is coated overnight at 4 ℃, the well plate is washed by PBST for 1 time, and then the antigen is blocked by PBS containing 3% Tween and coated overnight at 4 ℃. After PBST washing the well plate 1 times, each immune mouse serum (or fusion culture after the detection of cell supernatant and screening of positive clone cells) is diluted 10 times respectively³、10⁴、10⁵、10⁶And adding the antibody into a reaction hole, taking the serum of the unimmunized mouse as a negative control, placing the reaction hole into a constant temperature box at 37 ℃ for reaction for 1h, adopting a Horse Radish Peroxidase (HRP) labeled goat anti-mouse as a secondary antibody for detection, adding a TMB chromogenic substrate for reaction, and reading OD450 of each reaction hole by using an enzyme labeling instrument.

1.5 antibody epitope analysis

The enzyme labeling plates are respectively coated with TM-Total, TM-EGF and TM-NT, the obtained monoclonal antibodies are detected, and according to the detection result, the antibodies are divided into two groups, wherein the group 1 is a core region group and is named as NT, and the group 2 is a non-core region group and is named as EGF, and the two groups are shown in Table 2.

1.6 characterization of antibody subclasses

The subclass analysis of the monoclonal antibody was performed using the cell culture supernatant according to the monoclonal antibody subclass identification kit of Sigma, and the results are shown in Table 2, in which the 1 (TM 1 described above) and 8 (TM 2) monoclonal antibodies performed well. The preservation number is CCTCC No: the antibody secreted by the cell line of C202063 is TM1, and the preservation number is CCTCC No: the antibody secreted by the cell line of C202064 is TM 2.

TABLE 2 summary of antibody information and characterization

1.7 preparation of monoclonal antibodies

Selecting cell line reacting with TM-Total, subcloning to fixed line, and performing amplification at 5 × 10⁵Injecting the density of each cell/mouse into the abdominal cavity of the mouse, collecting ascites in 7-14 days, performing affinity purification by Protein A, determining the Protein concentration by a micro spectrophotometer, and determining the antibody purity by SDS-PAGE.

1.8 potency assay of antibodies

The indirect ELISA method is used for determination, the purified antibody is adjusted to 1mg/mL by PBS, and the antibody is respectively diluted to 10 by PBST containing 1% Tween³、10⁴、10⁵、10⁶And (4) multiplying. On ELISA detector, at 450nm (410 nm if developed by ABTS), using negative control hole to adjust zero, and if OD is greater than 2.1 times of specified negative control OD value, it is positive, and the result is shown in FIG. 2 (taking screened TM1 and TM2 with optimal performance as example), the titer can reach 1/10⁵。

1.9 antibody sensitivity assay

The indirect ELISA method is used for determination, TM-Total antigen is diluted by 2 times by using coating solution from 1 mu g/mL, 12 gradients are covered, an enzyme label plate is coated, purified antibody is adjusted to 1mg/mL by PBS, finally the purified antibody is diluted to 1 mu g/mL by using 1% Tween PBST, and the operation is carried out according to the ELISA experimental flow of the traditional brief introduction. And (4) carrying out zero setting on the negative control wells, then measuring the value of each well, and if the OD is more than 2.1 times of the specified negative control OD value, determining that the well is positive, and determining the corresponding dilution as the sensitivity of the antibody. The results are shown in FIG. 3 (taking TM1 and TM2 with the best performance and TM3 obtained by screening as examples), and the sensitivity of both TM1 and TM2 can reach below 1ng/mL in the method.

2 establishment of chemiluminescent TM detection reagent

2.1 anti-TM monoclonal antibody TM1 coated magnetic microparticles

First, 20mg/mL of MPs were placed in a 2.0mL EP tube and the MPs were washed five times with binding buffer. During the wash, the EP tube was placed on a magnetic concentrator and the supernatant was removed. Then, the MPs were resuspended in 2mL of binding buffer, the antibody solution was added to the suspension, and the mixture was incubated overnight at 37 ℃ with shaking. After incubation, the EP tubes were placed in a magnetic concentrator to separate them from the supernatant. The residual binding sites on the MPs were blocked with 3% Bovine Serum Albumin (BSA), incubated at 37 ℃ and shaken gently for 2 hours. After 5 washes, the magnetic bead-coated antibody (mAb-MPs) was dispersed in 2mL of buffer and stored at 4 ℃ until use.

2.2 preparation of alkaline phosphatase-labeled anti-TM monoclonal antibody TM2

First, Alkaline Phosphatase (AP) and an anti-TM monoclonal antibody TM2 recognizing another site were suspended in ultrapure water and diluted to 4mg/mL and 8mg/mL, respectively. A250. mu.L aliquot of the 4mg/mL AP solution was transferred to a 1.5mL EP tube and mixed with 250. mu.L of an 8mg/mL anti-TM monoclonal antibody solution. Next, 0.5mL of 0.1mol/L phosphate buffer (pH7.4) containing 1% glutaraldehyde was added to the solution. The resulting mixture was incubated at 37 ℃ in the dark with gentle shaking for 4 hours. In the third step, 0.1mL of a 1mol/L monoethanolamine solution was added to the mixture, followed by incubation at room temperature for 2 hours with shaking. The mixture was dialyzed overnight at 4 ℃ against PBS solution, after which the enzyme-labeled antibody was transferred to an EP tube and mixed with an equal volume of glycerol and 1% BSA. Finally, the enzyme-labeled antibodies (AP-mAbs) were stored at-20 ℃ until use.

2.3 MPs-based full-automatic chemiluminescence method for detecting TM

And (3) performing TM detection on a full-automatic chemiluminescence instrument by using a sandwich reaction mode of magnetic bead coated antibodies (mAb-MPs) and enzyme-labeled antibodies (AP-mAbs). First, 50 μ L of different concentrations of mAb-MP and CPP samples or standards (30 μ L) were pipetted into instrument-matched tubes, respectively, and incubated at 37 ℃ for 20 minutes with gentle shaking (capture time). The tube was then washed 3 times through a washing station with a washing solution (0.01 mol/L PBS containing 0.05% Tween) to remove non-specific binding. AP-mAbs were then added and incubated at 37 ℃ for 10 minutes with gentle shaking. At this point, the sandwich immune complex MPs-TM-AP is formed. The resulting sandwich immunocomplexes are magnetically separated and excess AP-mAbs are removed by washing. Subsequently, a solution containing the luminescent substrate AMPPD (200 μ L) was added to the sandwich complex. The resulting mixture was incubated in an immunoassay instrument and the value of Relative Light Units (RLU) was measured.

2.4 optimization and Performance evaluation of immunoassay reagents

A series of diluted AP-mAbs (1:50, 1:100, 1:200, 1:00,) and mAb-MPs (1:20, 1:50, 1:100, 1:200, 1:500) were reacted with a standard positive calibrator for TM (S3, 10TU/mL) and a negative sample (S0, 0TU/mL) and the optimal dilution was determined at the maximum RLU ratio of the two (RLUS3/RLUS 0). Based on the optimal combination, a standard curve is drawn as shown in fig. 4, the sensitivity and linear interval thereof are determined, and 100 clinical samples are analyzed in comparison with the schirmecane chemiluminescence reagent to investigate the feasibility of the newly developed immunoassay method. Results as shown in table 3 and fig. 5, positive compliance rates for the test agents: 92.86%, negative match: 97.73%, total percent of pass: 95 percent.

TABLE 3 clinical tests

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Sequence listing

<110> guangzhou Wanfu Biotechnology Co., Ltd

<120> hybridoma cell, anti-thrombomodulin monoclonal antibody, preparation method and application thereof

<160> 3

<170> SIPOSequenceListing 1.0

<210> 1

<211> 346

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 1

His Phe Pro Ala Thr Cys Arg Pro Leu Ala Val Glu Pro Gly Ala Ala

1 5 10 15

Ala Ala Ala Val Ser Ile Thr Tyr Gly Thr Pro Phe Ala Ala Arg Gly

20 25 30

Ala Asp Phe Gln Ala Leu Pro Val Gly Ser Ser Ala Ala Val Ala Pro

35 40 45

Leu Gly Leu Gln Leu Met Cys Thr Ala Pro Pro Gly Ala Val Gln Gly

50 55 60

His Trp Ala Arg Glu Ala Pro Gly Ala Trp Asp Cys Ser Val Glu Asn

65 70 75 80

Gly Gly Cys Glu His Ala Cys Asn Ala Ile Pro Gly Ala Pro Arg Cys

85 90 95

Gln Cys Pro Ala Gly Ala Ala Leu Gln Ala Asp Gly Arg Ser Cys Thr

100 105 110

Ala Ser Ala Thr Gln Ser Cys Asn Asp Leu Cys Glu His Phe Cys Val

115 120 125

Pro Asn Pro Asp Gln Pro Gly Ser Tyr Ser Cys Met Cys Glu Thr Gly

130 135 140

Tyr Arg Leu Ala Ala Asp Gln His Arg Cys Glu Asp Val Asp Asp Cys

145 150 155 160

Ile Leu Glu Pro Ser Pro Cys Pro Gln Arg Cys Val Asn Thr Gln Gly

165 170 175

Gly Phe Glu Cys His Cys Tyr Pro Asn Tyr Asp Leu Val Asp Gly Glu

180 185 190

Cys Val Glu Pro Val Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln

195 200 205

Cys Gln Pro Leu Asn Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly

210 215 220

Phe Ala Pro Ile Pro His Glu Pro His Arg Cys Gln Met Phe Cys Asn

225 230 235 240

Gln Thr Ala Cys Pro Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys

245 250 255

Glu Cys Pro Glu Gly Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp

260 265 270

Ile Asp Glu Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn

275 280 285

Leu Pro Gly Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala

290 295 300

Arg His Ile Gly Thr Asp Cys Asp Ser Gly Lys Val Asp Gly Gly Asp

305 310 315 320

Ser Gly Ser Gly Glu Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu

325 330 335

Thr Pro Pro Ala Val Gly Leu Val His Ser

340 345

<210> 2

<211> 151

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 2

Ala Pro Ala Glu Pro Gln Pro Gly Gly Ser Gln Cys Val Glu His Asp

1 5 10 15

Cys Phe Ala Leu Tyr Pro Gly Pro Ala Thr Phe Leu Asn Ala Ser Gln

20 25 30

Ile Cys Asp Gly Leu Arg Gly His Leu Met Thr Val Arg Ser Ser Val

35 40 45

Ala Ala Asp Val Ile Ser Leu Leu Leu Asn Gly Asp Gly Gly Val Gly

50 55 60

Arg Arg Arg Leu Trp Ile Gly Leu Gln Leu Pro Pro Gly Cys Gly Asp

65 70 75 80

Pro Lys Arg Leu Gly Pro Leu Arg Gly Phe Gln Trp Val Thr Gly Asp

85 90 95

Asn Asn Thr Ser Tyr Ser Arg Trp Ala Arg Leu Asp Leu Asn Gly Ala

100 105 110

Pro Leu Cys Gly Pro Leu Cys Val Ala Val Ser Ala Ala Glu Ala Thr

115 120 125

Val Pro Ser Glu Pro Ile Trp Glu Glu Gln Gln Cys Glu Val Lys Ala

130 135 140

Asp Gly Phe Leu Cys Glu Phe

145 150

<210> 3

<211> 312

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 3

His Phe Pro Ala Thr Cys Arg Pro Leu Ala Val Glu Pro Gly Ala Ala

1 5 10 15

Ala Ala Ala Val Ser Ile Thr Tyr Gly Thr Pro Phe Ala Ala Arg Gly

20 25 30

Ala Asp Phe Gln Ala Leu Pro Val Gly Ser Ser Ala Ala Val Ala Pro

35 40 45

Leu Gly Leu Gln Leu Met Cys Thr Ala Pro Pro Gly Ala Val Gln Gly

50 55 60

His Trp Ala Arg Glu Ala Pro Gly Ala Trp Asp Cys Ser Val Glu Asn

65 70 75 80

Gly Gly Cys Glu His Ala Cys Asn Ala Ile Pro Gly Ala Pro Arg Cys

85 90 95

Gln Cys Pro Ala Gly Ala Ala Leu Gln Ala Asp Gly Arg Ser Cys Thr

100 105 110

Ala Ser Ala Thr Gln Ser Cys Asn Asp Leu Cys Glu His Phe Cys Val

115 120 125

Pro Asn Pro Asp Gln Pro Gly Ser Tyr Ser Cys Met Cys Glu Thr Gly

130 135 140

Tyr Arg Leu Ala Ala Asp Gln His Arg Cys Glu Asp Val Asp Asp Cys

145 150 155 160

Ile Leu Glu Pro Ser Pro Cys Pro Gln Arg Cys Val Asn Thr Gln Gly

165 170 175

Gly Phe Glu Cys His Cys Tyr Pro Asn Tyr Asp Leu Val Asp Gly Glu

180 185 190

Cys Val Glu Pro Val Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln

195 200 205

Cys Gln Pro Leu Asn Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly

210 215 220

Phe Ala Pro Ile Pro His Glu Pro His Arg Cys Gln Met Phe Cys Asn

225 230 235 240

Gln Thr Ala Cys Pro Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys

245 250 255

Glu Cys Pro Glu Gly Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp

260 265 270

Ile Asp Glu Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn

275 280 285

Leu Pro Gly Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala

290 295 300

Arg His Ile Gly Thr Asp Cys Asp

305 310

Claims

1. A hybridoma cell capable of secreting an anti-thrombomodulin monoclonal antibody is characterized in that the preservation number is CCTCC NO: C202064.

2. an anti-thrombomodulin monoclonal antibody secreted by the hybridoma cell according to claim 1, wherein the anti-thrombomodulin monoclonal antibody is designated as TM 2.

3. A preparation method of an anti-thrombomodulin monoclonal antibody is characterized by comprising the following steps: injecting the hybridoma cell of claim 1 into the abdominal cavity of a mouse, collecting ascites, separating and purifying to obtain the anti-thrombomodulin monoclonal antibody.

4. The method of claim 3, wherein the intraperitoneal injection is performed by injecting 4 x 10 per mouse⁵～6×10⁵And (c) the hybridoma cells.

5. Use of the hybridoma cell of claim 1 or the anti-thrombomodulin monoclonal antibody of claim 2 for the preparation of a product for the detection of thrombomodulin.

6. A thrombomodulin detection kit comprising the anti-thrombomodulin monoclonal antibody of claim 2.

7. The thrombomodulin detection kit according to claim 6, characterized by further comprising magnetic microparticles and alkaline phosphatase.

8. The thrombomodulin detection kit according to claim 7, characterized by further comprising Tween and a phosphate buffer.

9. A method for preparing the hybridoma cell of claim 1, comprising the steps of:

taking a mouse to immunize for the first time by taking thrombomodulin as immunogen, wherein the amino acid sequence of the thrombomodulin is shown as SEQ ID NO: 1 is shown in the specification;

10. The method of claim 9, wherein said spleen cells are fused to said myeloma cells by electrofusion.